PI-RADS Upgrades Predict Clinically Significant Prostate Cancer in Initial PI-RADS-3 Lesions

Overview

In patients with initial PI-RADS 3 prostate lesions, upgrading to PI-RADS 4 or 5 on follow-up mpMRI was the strongest independent predictor of clinically significant prostate cancer (csPCa). Systematic biopsy detected more csPCa than targeted biopsy in PI-RADS 3 and 4 lesions. Other clinical parameters, including PSA density and ERSPC risk calculators, showed limited predictive accuracy.

Background

Multiparametric MRI (mpMRI) is standard in prostate cancer detection and guides biopsy decisions. PI-RADS 3 lesions are equivocal, and their management remains controversial due to inconsistent data on their clinical significance. Current guidelines recommend combined systematic and targeted biopsy for suspicious lesions, but no consensus exists on handling PI-RADS 3 findings. This study evaluated follow-up imaging and biopsy results to identify predictors of csPCa in patients initially presenting with PI-RADS 3 lesions.

Data Highlights

Key Findings

• PI-RADS upgrading from 3 to 4 or 5 on follow-up mpMRI was the only independent predictor of csPCa in uni- and multivariate analyses.
• Systematic biopsy detected significantly more csPCa than targeted biopsy in patients with PI-RADS 3 and 4 lesions.
• CsPCa detection rates increased markedly with higher PI-RADS categories: 3.4% for <3, 11.6% for 3, 42.3% for 4, and 50% for 5.
• PSA density and ERSPC risk calculators showed limited accuracy (AUCs around 0.45–0.55) for predicting csPCa in this cohort.
• More than half of patients (54.8%) had stable PI-RADS 3 findings on follow-up mpMRI, with a minority showing downgrading or upgrading.

Clinical Implications

Patients with initial PI-RADS 3 lesions should undergo follow-up mpMRI to monitor for PI-RADS upgrading, which strongly predicts clinically significant prostate cancer. Systematic biopsy remains important, especially in PI-RADS 3 and 4 lesions, as it detects more csPCa than targeted biopsy alone. Reliance on PSA density or risk calculators alone may be insufficient to guide biopsy decisions in this group.

Conclusion

PI-RADS upgrading on follow-up mpMRI is the most significant indicator of clinically relevant prostate cancer in patients initially presenting with PI-RADS 3 lesions. Incorporating imaging changes with systematic biopsy improves detection of csPCa and informs clinical management.

References

1. EAU Guidelines 2023 -- Prostate Cancer Detection and Biopsy Recommendations
2. ERSPC Risk Calculator -- http://www.prostatecancer-riskcalculator.com/